Form 4: Vaxcyte COO Jim Wassil Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares on December 2, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On December 2, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte, Inc., exercised stock options to acquire 8,000 shares of common stock at a price of $2.42 per share.
- Concurrently, Mr. Wassil sold a total of 8,000 shares of Vaxcyte common stock in multiple transactions at weighted average prices ranging from $92.068 to $94.062 per share.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 1, 2024.
- Following these transactions, Mr. Wassil directly owns 205,695 shares of Vaxcyte common stock and 18,638 stock options.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by an executive, and does not contain any information that would be considered positive or negative for the company's outlook.
Industry Context
This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading.
Comparison to Industry Standards
- The use of a 10b5-1 trading plan is a standard practice among corporate executives to manage their stock transactions.
- The reported prices are within the typical range for stock transactions of this nature.
- The vesting schedule of the stock options is also typical for executive compensation packages.
Stakeholder Impact
- The transactions have a minimal impact on stakeholders as they are part of a pre-arranged trading plan.
Key Dates
| Date | Description |
|---|---|
| 2020-12-01 | 1/4 of the shares subject to the option vested on this date. |
| 2024-03-01 | Date the Rule 10b5-1 trading plan was adopted. |
| 2024-12-02 | Date of the stock option exercise and share sales. |
| 2024-12-03 | Date the Form 4 was signed. |
| 2029-12-16 | Expiration date of the stock options. |
Keywords
Vaxcyte, insider trading, stock options, Rule 10b5-1, Jim Wassil, stock sale, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.